Author(s):
S Narendra Kumar, Chetan D M, Lingayya Hiremath, Ajeet Kumar Srivastava, Muralidhara P L, Jyothsana R, Rithika Pravin Iye, Ruchika Pravin Iyer
Email(s):
narendraks@rvce.edu.in
DOI:
10.52711/0974-360X.2022.00535 
Address:
S Narendra Kumar1, Chetan D M2, Lingayya Hiremath3, Ajeet Kumar Srivastava4, Muralidhara P L5, Jyothsana R6, Rithika Pravin Iye7, Ruchika Pravin Iyer8
1,3,4Assistant Professor, Department of Biotechnology, RV College of Engineering, Bangalore.
2Associate Professor, Department of Biotechnology, NMAMIT, NITTE, Karkala.
5Assistant Professor, Department of Chemical Engineering, RV College of Engineering, Bangalore.
6,7,8BE-Graduate Students, R V College of Engineeering, Bengaluru.
*Corresponding Author
Published In:
Volume - 15,
Issue - 7,
Year - 2022
ABSTRACT:
Cancer is a group of diseases which involves abnormal cell growth that can spread to other parts of the body. There are certain characteristics that are required to produce a malignant tumour. They include: Avoidance of programmed cell death and uncontrolled cell division to name a few. The progression from normal cells to cells that can form a detectable mass to outright cancer involves multiple steps known as malignant progression. Cannabinoids are among the treatment available. Recent research has shown that cannabinoid coupled with hydroxy citric acid can be used in the treatment of melanoma. Hydroxy citric acid is a derivative of citric acid well known for its anti-obesity and anti-inflammatory property. The current project involves the coupling of tetrahydrocannabinol with hydroxy citric acid to develop a novel drug molecule for potential cancer treatment. Simulation tool like Argus lab is used to construct the 3D structure of the novel drug. Autodock was used to bind the drug with the receptors like TRPV1, CB1, CB2, 4QO1 and 2YGB.
Cite this article:
S Narendra Kumar, Chetan D M, Lingayya Hiremath, Ajeet Kumar Srivastava, Muralidhara P L, Jyothsana R, Rithika Pravin Iye, Ruchika Pravin Iyer. Molecular Docking studies of THC-HCA on Cancer Receptors. Research Journal of Pharmacy and Technology. 2022; 15(7):3195-9. doi: 10.52711/0974-360X.2022.00535
Cite(Electronic):
S Narendra Kumar, Chetan D M, Lingayya Hiremath, Ajeet Kumar Srivastava, Muralidhara P L, Jyothsana R, Rithika Pravin Iye, Ruchika Pravin Iyer. Molecular Docking studies of THC-HCA on Cancer Receptors. Research Journal of Pharmacy and Technology. 2022; 15(7):3195-9. doi: 10.52711/0974-360X.2022.00535 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-7-57
REFERENCE:
1. L. Cristino L. De Petrocellis G. Pryce, D. Baker V. Guglielmotti And V. Di Marzo,” Immunohistochemical Localization of Cannabinoid Type 1 And Vanilloid Transient Receptor Potential Vanilloid Type 1 Receptors In The Mouse Brain”, Neuroscience 139 (2006) 1405–1415.
2. Luciano De Petrocellis, Vittorio Vellani, Aniello Schiano-Moriello, Pietro Marini, Pier Cosimo Magherini, Pierangelo Orlando and Vincenzo Di Marzo,” Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 (TRPA1) and melastatin type-8 (TRPM-8)”, American Society for Pharmacology and Experimental Therapeutics, March 19, 2008, 1-36.
3. Sara Caprodossi, Cristina Kalogris, Consuelo Amantini, Federica Lambertucci, Massimo Nabissi, et al.. Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: relation to clinico-pathological and molecular parameters.. Histopathology, Wiley, 2010, 57 (5), pp.744. <10.1111/j.1365-2559.2010.03683.x>. <hal-00593446>
4. Ann M. Bode, Yong-Yeon Cho,Duo Zheng, Feng Zhu, Marna E. Ericson, Wei-Ya Ma, Ke Yaoand Zigang Dong,” Transient Receptor Potential Type Vanilloid 1 Suppresses Skin Carcinogenesis”, AACR journal, January 20 2009, 905-913.
5. Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee CH, Sullivan JP, Faltynek CR (2006). "TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists". J. Neurosci. 26 (37): 9385–93.
6. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (June 2002). "An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors". Proc. Natl. Acad. Sci. U.S.A. 99 (12): 8400–5.
7. Christos S. Karapetis, M.D., Shirin Khambata-Ford, Ph.D., Derek J.Jonker, M.D., Chris J. O'Callaghan, Ph.D., Dongsheng Tu, Ph.D., Niall C. Tebbutt, Ph.D., R. John Simes, M.D., Haji Chalchal, M.D., Jeremy D. Shapiro, M.D., Sonia Robitaille, M.Sc., Timothy J. Price, M.D., Lois Shepherd M.D.C.M., “K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer” The New England Journal of Medicine October 23 2008.
8. Jonathan M. Ostrem, Ulf Peters, Martin L. Sos, James A. Wells &Kevan M. Shokat “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions” Naturevolume 503, pages 548–551 (28 November 2013).
9. Kevin M Haigis, Krystle R Kendall, Yufang Wang, Ann Cheung, Marcia C Haigis, Jonathan N Glickman, Michiko Niwa-Kawakita, Alejandro Sweet-Cordero, Judith Sebolt-Leopold, Kevin M Shannon, Jeffrey Settleman, Marco Giovannini and Tyler Jacks “Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon” Nature Geneticsvolume 40, pages 600–608 (2008)
10. David W.Meek“Regulation of the p53 response and its relationship to cancer”. Biochemical Journal Jul 23, 2015, 469 (3) 325-346.
11. E C Pietsch, S M Sykes, S B McMahon and M E Murphy” The p53 family and programmed cell death” Oncogene volume 27, pages 6507–6521 (27 October 2008).
12. Qian Hao and William C. Cho “Battle against Cancer: An Everlasting Saga of p53”. International Journal of Molecular Science 2014, 15(12), 22109-22127.
13. Andreas C. Joerger and Alan R. Fersht” Structural biology of Tumour Suppressor” Annnual Review of Biochemistry 2008 Vol: 77:557-582.
14. Shenglong Zou and Ujendra Kumar,’ Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System’,Int J Mol Sci. 2018 Mar; 19(3): 833.
15. Basu S, Ray A, Dittel BN (Dec 2011). "Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses". Journal of Immunology. 187 (11): 5720–32.
16. Kristina L Leinw, Ashleigh A Jones, “Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease”Journal of Crohn's and Colitis, Volume 11, Issue 11, 27 October 2017, Pages 1369–1380.
17. G. A. Cabral* and L. Griffin-Thomas,”Emerging Role of the CB2 Cannabinoid Receptor in Immune Regulation and Therapeutic Prospects”,Cambridge University Press,Volume 11, July 2009, e3.
18. Caroline Turcotte, Marie-Renée Blanchet, Michel Laviolette, and Nicolas Flamand,” The CB2 receptor and its role as a regulator of inflammation”, Cell Mol Life Sci. 2016; 73(23): 4449–4470.
19. K L Wright, M Duncan, and K ASharkey,”Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation”, Br J Pharmacol. 2008 Jan; 153(2): 263–270.
20. Abood M, Barth F, Bonner TI, Cabral G, Casellas P, Cravatt BF, Devane WA, Elphick MR, Felder CC, Herkenham M, Howlett AC, Kunos G, Mackie K, Mechoulam R, Pertwee RG (22 August 2018). "CB1 Receptor". IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. Retrieved 9 November 2018.
21. "Entrez Gene: CNR1 cannabinoid receptor 1 (brain)".
22. Thomas, Adèle; Stevenson, Lesley A; Wease, Kerrie N; Price, Martin R; Baillie, Gemma; Ross, Ruth A; Pertwee, Roger G (December 2005). "Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist". British Journal of Pharmacology. 146 (7): 917–926.
23. Srivastava MD, Srivastava BIS, Brouhard B. Delta-9-tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology. 1998;40:179–185
24. Ladin D. A., Soliman E., Griffin L., Van Dross R. (2016). Preclinical and clinical assessment of cannabinoids as anti-cancer agents. Front. Pharmacol. 7:361.
25. Preet A, Ganju RK, Groopman JE. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008;27: 339–46.
26. Ellert-Miklaszewska A, Kaminska B, Konarska L. Cannabinoids downregulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 2005;17:25–37.